

Electronic Supplementary Information (ESI)

Glypican-3 antibody functionalized prussian blue nanoparticles for targeted MR imaging and photothermal therapy of hepatocellular carcinoma†

Zhenglin Li ^{#,1,2}, Yongyi Zeng ^{#,1,2,3}, Da Zhang ^{1,2}, Ming Wu ^{1,2}, Lingjie Wu ^{1,2}, Aimin Huang ^{2,4}, Huanghao Yang ⁵, Xiaolong Liu ^{*,1,2}, Jingfeng Liu ^{*,1,2,3}

1. Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350025, P. R. China.
2. The Liver Center of Fujian Province, Fujian Medical University, Fuzhou 350025, P. R. China.
3. Liver Disease Center, The First Affiliated Hospital of Fujian Medical University, Fuzhou 350007, P. R. China.
4. Department of Pathology, School of Basic Medical Science, Fujian Medical University, Fuzhou 350004, P. R. China.
5. The Key Lab of Analysis and Detection Technology for Food Safety of the MOE, College of Chemistry, Fuzhou University, Fuzhou 350002, P. R. China.

* Corresponding author (Correspondence should be addressed to X. Liu and JF. Liu),

Equal Contribution Authorship.

Tel.: +86591-83705927; Fax: +86591-83705927.

E-mail address: xiaoloong.liu@gmail.com (X. Liu), drjingfeng@126.com (JF. Liu).




Figure S1. Morphological characterization of antiGPC3-PBNPs with a bigger particle size (~ 118 nm). (a) (b)SEM. (c) (d)TEM.




Figure S2. Fluorescence emission spectrum of FITC-antiGPC3-PBNPs.




Figure S3. The proton T_1 (a) and T_2 (b) relaxation rate versus concentration of Fe^{3+} in antiGPC3-PBNPs at 9.4 T.




Figure S4. Size distribution of the PBNPs (a) and antiGPC3-PBNPs (b), and zeta potential distribution of the PBNPs (c) and antiGPC3-PBNPs (d) in DI-water, as determined by DLS analysis.